The aim of this prospective randomized study was to compare the effects of the transfusion of unprocessed and cell saver-processed residual cardiopulmonary bypass (CPB) volume on haemostasis, complement activation, postoperative blood loss and transfusion requirements after elective cardiac surgery. Blood samples were taken at eight points in time, perioperatively. Haematological data, including haemoglobin, haematocrit and platelet counts as well as coagulation parameters, including activated partial thromboplastin time, prothrombin time, thrombin time, fibrinogen and the fibrinolytic parameter D-dimers, were measured from each blood sample. For the assessment of complement activation, the total complement CH50 was analysed. In addition, postoperative blood loss and transfusion requirements were measured during the first 24 hours, postoperatively. The results of the study showed impaired haemostasis after the transfusion of both unprocessed and processed CPB volume. No significant differences were found between the groups in the measured coagulation parameters. Nor was a significant difference found in the complement concentration. However, in patients transfused with unprocessed CPB volume, a significantly (p = 0.019) higher amount of blood loss was found, postoperatively. In the same group of patients, the number of units of allogeneic erythrocyte concentrate suspension transfused was also significantly (p = 0.023) higher during the first 24 hours, postoperatively, compared to the patients transfused with processed CPB blood. The number of units of fresh frozen plasma and platelet suspension transfused was not significantly different between the groups. In conclusion, processing CPB volume in combination with processing peroperative blood loss may result in reducing the volume of transfusion needed of allogeneic blood products.
The COP regulatory strategy for neonatal and infant CPB, based upon the 5% concentration of albumin in the priming and a COP target of 18 mmHg during bypass, better preserves the plasma albumin concentration within the physiological range and stabilizes the colloid pressure than the standard strategy (0.5 gkg(-1) albumin in the priming and bypass COP target at 15 mmHg). Nevertheless, only the lower postoperative plasma lactate concentration and the shorter duration of mechanical ventilation in the high COP group indicated the potential clinical benefit of this new strategy.
Intraoperative cell salvage, employed as an adjuvant technique to the residual volume salvage in infants undergoing first time cardiac surgery with cardiopulmonary bypass, was a safe and effective method to reduce postoperative allogeneic blood transfusion. Considering current cell salvage related expense and the cost reduction achieved by diminished allogeneic transfusion, intraoperative cell salvage in infants demonstrated no economic benefit.
Cardiopulmonary bypass in children may cause severe hemodilution and can lead to excessive perioperative blood loss and high transfusion requirements. Minimization of cardiopulmonary bypass circuit and salvage of red blood cells from the residual volume after the procedure are widely utilized to reduce allogeneic transfusion. We evaluated the effectiveness of those measures introduced in infant cardiac surgery in our institution. This retrospective observational study included 148 consecutive infants between 1 and 12 months of age, with a body weight <10 kg, who underwent an elective cardiac operation between 1997 and 2005. Patients were divided into three groups defined by the circuit prime volume; 700 ml (Group 1), 450 ml (Group 2) and 330 ml (Group 3). In Group 1 residual volume after perfusion was discarded and in Groups 2 and 3 was processed in a cell saving device. Analyzed variables were: perioperative blood loss, transfusion of homologous blood products and cell salvage product, and hematology data. Reduction of the circuit volume significantly diminished use of red blood cell concentrates from 1.6 units to 0.8 units (P<0.0001), and fresh frozen plasma from 1.3 units to 0.4 units (P<0.0001). Utilization of the cell salvage product reduced significantly (P=0.023) the postoperative need for homologous blood transfusion. Therefore, both measures proved to be effective in reducing homologous blood transfusion in infant cardiac surgery.
Introduction:Postoperative delirium is the most common neurological complication of
cardiac surgery. Hypoxia has been shown to increase the risk of
postoperative delirium. The possibility to continuously monitor oxygen
delivery (DO2) during cardiopulmonary bypass (CPB) offers an
adequate approximation of the oxygen status in a patient. This study
investigates the role of oxygen delivery during cardiopulmonary bypass in
the incidence of postoperative delirium.Methods:Three hundred and fifty-seven adult patients who underwent normothermic
coronary artery bypass grafting (CABG) surgery were included in this
retrospective study. The nadir indexed DO2 (DO2i)
value on bypass, the total time under the critical DO2i level and
the area under the curve (AUC) for critical DO2i were determined.
Delirium was identified by the postoperative administration of
haloperidol.Results:The mean nadir DO2i significantly differed, comparing the group of
patients with postoperative delirium to the group without. Multivariate
analysis only identified age, pre-existing cognitive impairment,
preoperative kidney dysfunction and cross-clamp time as independent risk
factors for delirium. The results also indicated that patients of older age
were more sensitive to a declined DO2i.Conclusion:A low DO2i during cardiopulmonary bypass is significantly
associated with the incidence of postoperative delirium in CABG patients.
However, the role of DO2 as an independent predictor of delirium
could not be proven.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.